USC Michelson Center for Convergent Bioscience scientists use metal-detection technique to map cancer cells at the molecular level

The Kuhn-Hicks laboratory are using metal-tagged antibodies to map the proteins expressed on cancer cells circulating in the blood and in the bone marrow from a prostate cancer patient.  The study, published in January by Convergent Science Physical Oncology, describes the approach of using an imaging mass cytometer to quantitate and localize 35 different protein markers...
Read More

New Educational Track to Train Undergraduates on Health Innovation to Help Patients Achieve Better Outcomes

USC’s Convergent Science Initiative in Cancer and the USC Jimmy Iovine and Andre Young Academy have developed a new interdisciplinary undergraduate track to launch in the fall of 2019. Students in this new educational track will interact with physicians, scientists, patients and graduate students to develop innovative health solutions. Click here to read more.

Liquid Biopsy for Retinoblastoma

Dr. James Hicks, professor of biologic sciences at the USC Michelson Center for Convergent Bioscience and professor at the Keck School of Medicine at USC, and Liya Xu, a postdoctoral fellow published work showing that the chromosomal changes in the DNA found in the eye’s aqueous humor parallel chromosomal changes found in the retinoblastoma tumor....
Read More

USC’s Global Convergent Science Initiative for a Patient-Centric Approach to Cancer Treatment and Research

Dr.  Peter Kuhn, Dean’s Professor of Biological Sciences and a founding member of the USC Michelson Center for Convergent Bioscience, traveled to Vietnam to discuss a multidisciplinary approach to understanding cancer evolution and forecasting an individual patient’s progress. One goal is to put the cancer patient at the center. Click here to read more.

Public Private Partnership Announced

The Kuhn laboratory at USC will lead a Public-Private Partnership launched by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to evaluate liquid biopsies as biomarker in patients with colorectal cancer undergoing hepatic metastasectomy using the HD-SCA platform.